Livedoid vasculopathy(LV)
Conditions
Interventions
Cohort 1:Rivaroxaban
Cohort 2:Rivaroxaban+Tofacitib
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1Diagnosed with LV based on clinical symptoms and histology; 2 Ages 18-75 (inclusive), regardless of gender; 3 Patients must have had a pain Visual Analogue Score of >=4 on at least one day within 7 days before the start of treatment; 4 LV patients who receive treatment with rivaroxaban plus tofacitinib or only rivaroxaban; 5 Understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1 Patients with acute or chronic mental illnesses; 2 All patients who have received systemic glucocorticoids, intravenous immunoglobulins, hyperbaric oxygen therapy, PUVA (psoralen and ultraviolet A) therapy, sulfasalazine, or dapsone within the past 4 weeks; those who have undergone anti-tumor necrosis factor-alpha monoclonal antibody treatment within the last 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain Visual Analogue Scale (VAS) scores;Proportion of patients with a =75% decrease in pain visual analogue scale (VAS) score from baseline ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermatology Quality of Life index(DLQI);Incidence of adverse events, serious adverse events.;Difference in Dermatological Life Quality Index (DLQI) compared to baseline; | — |
Countries
China
Contacts
Public ContactJuan Bai
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed